T. Rowe Price Investment Management, Inc.
Position in ELVN — Enliven Therapeutics, Inc.
CIK 1897612
BALTIMORE, MD
Position in ELVN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$15,270,218
New position
Shares Held
300,891
first reported quarter
Ownership
0.411%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#56
of 208 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026T. Rowe Price Investment Management, Inc. holds $12,244,164,567 across 51 Biotechnology names. ELVN ranks #44 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
6,754,846 | $1,801,652,525 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
5,642,173 | $1,698,463,338 | |
| 3 | CYTK |
Cytokinetics Inc
|
18,718,498 | $1,594,628,844 | |
| 4 | KYMR |
Kymera Therapeutics, Inc.
|
6,257,261 | $717,520,118 | |
| 5 | PCVX |
Vaxcyte, Inc.
|
12,207,450 | $709,619,068 | |
| 6 | DYN |
Dyne Therapeutics, Inc.
|
30,912,287 | $686,561,894 | |
| 7 | CGON |
CG Oncology, Inc.
|
6,616,899 | $470,130,673 | |
| 8 | IMNM |
Immunome Inc.
|
19,676,883 | $416,953,150 |
All Filings in ELVN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $15,270,218 | 300,891 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||